Precipio Inc. (PRPO) 12-Month Stock Forecast & Price Target Cone

$18.10 -6.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $17.86

Precipio Inc. (PRPO) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $32.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PRPO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PRPO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Precipio Inc. (NASDAQ: PRPO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $18.10 (-6.46% 1D, market cap $32.4M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, PRPO ranks #811 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PRPO compare to EYPT and RPID in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), PRPO carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 44.2%, and ROIC of -7.9%. By comparison, EYPT (EyePoint Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $30.0M) and RPID (Rapid Micro Biosystems Inc. (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $36.9M). Among the 5-stock peer group, PRPO leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PRPO?
▼

Per PRPO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001043961), Precipio Inc. generated $24.2M in revenue (+30.5% YoY), -$363.0K in net income, and $359.0K in free cash flow against $21.3M in total assets and $47.0K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $17.86 (-1.35%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 1.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510030
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (5)Whales (3)SEC (7)Macro (9)CEO (6)
Each axis scored 0–20
12M PRICE TARGET CONE-12.6% Base Target
$35 Bull$16 Base$12 Bear
📬 FREE PRPO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRPO)Realized 20D OHLCV Swing Band: ±10.3%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY PRPO SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+9/20 pts (30% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 31.3 (OVERSOLD (<32))

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+7/20 pts (23% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
38
Grade E$22.59-3.9% Next Q
Q2 (-2Q)
35
Grade E$21.72-12.9% Next Q
Q3 (-1Q)
33
Grade E$18.91-4.3% Next Q
Current
30
Grade E$18.10-9.6% Hist 90D α
Trajectory: E (38) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PRPO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PRPO currently carries a cautious 30/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($24.10) and Max Pain ($19.01) forces dealer call-delta covering toward $35.31.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRPO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PRPO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your PRPO Position Size: $10,000

Shares at $18.10: 552.5 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $12.34
$6,818
$-3,182 (-31.8%)
12M Consensus BaseTarget $15.82
$8,740
$-1,260 (-12.6%)
12M Bull Case BreakoutTarget $35.31
$19,508
+$9,508 (+95.1%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$1674%A
Goldman SachsSector Coverage LeadUNDERPERFORM$3369%B
JP MorganUS Large-Cap ResearchSELL$1458%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRPO)

  • ✓Walkthrough of PRPO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PRPO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -39.06%🛡️ HOLDING TREND SUPPORT
2026-11-03O $19.35H $19.35L $18.10C $18.10VOL 25.9K
RES: $31.91SUP: $17.95SMA50: $24.10SMA200: $24.94
$34.72$30.19$25.65$21.12$16.58RES $31.91SUP $17.95$18.102026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRPO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +30.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PRPO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PRPO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PRPO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRPO)

Health Care Rank #811 of 1016 ⚔️ EYPT vs PRPO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PRPO vs. EYPT, RPID, HBIO, BNGO)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Precipio Inc. (PRPO) ranks #811 by composite RQD confidence (30/100, grade E) and #789 by equity capitalization ($32.4M). Within this direct 5-issuer industry benchmark cohort, PRPO leads on earnings valuation at N/A trailing P/E, while PRPO leads on capital efficiency and profitability with -7.9% ROIC and 44.2% gross margin. HBIO currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with PRPO at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PRPO ACTIVE
Precipio Inc.
E 30/100 — 44.2% -7.9% -6.46% $32.4M Benchmark Subject
EYPT
EyePoint Inc.
E 26/100 — — -35.0% -8.32% $30.0M /eypt-vs-prpo →
RPID
Rapid Micro Biosystems Inc. (Class A)
E 34/100 — — -35.0% -6.73% $36.9M /rpid-vs-prpo →
HBIO
Harvard Bioscience Inc.
D 47/100 — 57.7% -35.0% +1.14% $40.5M /hbio-vs-prpo →
BNGO
Bionano Genomics Inc.
E 29/100 — 46.3% -35.0% -4.17% $16.1M /bngo-vs-prpo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001043961

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Precipio Inc. (PRPO) reported GAAP revenue of $24.2M (+30.5% vs. FY2024 revenue of $18.6M , and +57.3% cumulative change since FY2023) , GAAP net income of -$363.0K, operating cash flow of $685.0K, and free cash flow of $359.0K (+66.2% YoY). On the balance sheet, PRPO closed FY2025 with $21.3M in total assets against $47.0K in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $24.2M -$363.0K $685.0K $359.0K $21.3M $47.0K
FY2024 (FY) 2024-12-31 $18.6M -$4.3M $439.0K $216.0K $17.0M $77.0K
FY2023 (FY) 2023-12-31 $15.4M -$5.9M -$3.6M -$3.6M — —

3. PRPO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRPO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Precipio Inc. (NASDAQ: PRPO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $18.10 (-6.46% 1D, market cap $32.4M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, PRPO ranks #811 in composite RQD confidence.

How does PRPO compare to EYPT and RPID in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), PRPO carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 44.2%, and ROIC of -7.9%. By comparison, EYPT (EyePoint Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $30.0M) and RPID (Rapid Micro Biosystems Inc. (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $36.9M). Among the 5-stock peer group, PRPO leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PRPO?

Per PRPO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001043961), Precipio Inc. generated $24.2M in revenue (+30.5% YoY), -$363.0K in net income, and $359.0K in free cash flow against $21.3M in total assets and $47.0K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PRPO trading relative to its 50-day, 200-day, and 52-week technical levels?

PRPO last traded at $18.10 (-6.46% on volume of 25,903 shares), positioning the stock -24.90% below its 50-day simple moving average ($24.10) and -27.43% below its 200-day simple moving average ($24.94). Across its 52-week range of $17.99 to $33.63, PRPO sits at the 0.7% percentile with a 14-day RSI of 31.3 (OVERSOLD (<32)) and an implied next-earnings move of ±10.3% ($16.24 to $19.96).

PRPO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is PRPO's 12-month stock price target?

Precipio Inc. (PRPO) carries a 12-month consensus base price target of $15.82 (-12.6% from $18.10), with a bull-case target of $35.31 and a bear-case floor of $12.34.

Is PRPO stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates PRPO E (Strong Sell — SELL) with an RQD Confidence score of 30/100.

ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PRPO — Precipio Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:48:14Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, PRPO scores 30 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The Fundamental Cash Engine pillar scores 5 out of 20, reflecting ROIC of -7.9% and an FCF yield of 1.04%, which indicates the business is not currently generating returns above its cost of capital. The Whale 13F Flow pillar scores 3 out of 20 for institutional accumulation and options positioning, the weakest pillar in the rating. The Insider Conviction pillar scores 6 out of 20 based on SEC Form 4 and Congressional PTR cluster flow. The Macro Regime Fit pillar scores 9 out of 20, with a beta of 1.0 and sector sensitivity noted. The Forensic Balance Sheet pillar scores 7 out of 20, combining an Altman Z-Score of 0.2 (a distress-zone reading), a Piotroski F-Score of 8 out of 9 (a strong operating-quality reading), and Debt/Equity of 0.5. The divergence between a high Piotroski score and a very low Altman Z-Score is the central tension in this rating: operating-quality signals are comparatively healthy, while the solvency-distress signal is severe. For a prospective investor, the rating implies limited near-term upside drivers from cash generation, a valuation with little fundamental support on the data provided, and balance-sheet fragility that increases downside risk if operating results do not improve. This analysis is educational and is not personalized financial advice.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$24.2M$-1.2M$-0.4MN/A$0.4M$2.7M$0.0M
FY 2024$18.6M$-4.2M$-4.3MN/A$0.2M$1.4M$0.1M
FY 2023$15.4M$-7.6M$-5.9MN/A$-3.6MN/AN/A

Per the SEC financials, revenue grew from $15.4M in FY 2023 to $24.2M in FY 2025, and operating losses narrowed from $-7.6M to $-1.2M over the same span. Per the market data, gross margin is 44.2%, operating margin is -5%, and net margin is -1.5%, with ROIC at -7.9%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 8 out of 9, with Debt/Equity at 0.5. Per the SEC financials, FY 2025 free cash flow was $0.4M and cash was $2.7M against debt of $0.0M.

Open Questions

  • What are the company's product lines, customer base, and revenue model, given that the business description is absent from the source data?
  • What are the reported EPS figures for FY 2023 through FY 2025, since the source lists EPS as N/A for every period?
  • Why does the profile report a market capitalization of $0.0B while the market data reports $34.6M, and which figure is reliable?
  • What is the source and basis for the "products revenue milestone" referenced in the news wire, and what does it measure?
  • What is the cash and debt position for FY 2023, which is recorded as N/A in the financials?

PRPO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Precipio Inc. (PRPO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PRPO Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PRPO Bull vs. Bear Conversation Board — What's Your Call at $18.10?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PRPO 🐻 67% BEARISH CONVICTION
1. Pick Your Side on PRPO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $17.03 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is PRPO (E • RQD 30/100) a Buy at $19.35?

Welcome to the PRPO (Precipio Inc.) Roar Pit. Current RQD Composite is 30/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Laboratory Analytical Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $15.29 (-21.0%)
Spot @ $19.35

Pump the brakes on PRPO — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PRPO, but look at what you are paying: current EV/EBITDA multiples with 44.2% gross margins. Unless Precipio Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $23.03 (+19.0%)
Spot @ $19.35

PRPO cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PRPO, the market is fixating on short-term headline noise in Biotechnology: Laboratory Analytical Instruments and ignoring the balance sheet and cash flow trajectory. At $19.35 (52-wk range $17.99 - $33.63), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%